UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*



Bone Biologics Corporation

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

098070303

(CUSIP Number)

 

 

December 31, 2023
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

CUSIP No.  098070303
 SCHEDULE 13G/A
Page 2 of 6 Pages

 

         
1
NAME OF REPORTING PERSONS
 
Walleye Capital LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) o
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Minnesota
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
0
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
0
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
0
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
0.0%
12
TYPE OF REPORTING PERSON
 
IA

 
 

 

CUSIP No.  098070303
 SCHEDULE 13G/A
Page 3 of 6 Pages

 

Item 1.(a) Name of Issuer

Bone Biologics Corporation

Item 1.(b) Address of Issuer’s Principal Executive Offices

2 Burlington Woods Drive Suite 100

Burlington, MA 01803

Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

Walleye Capital LLC, a Minnesota limited liability company

315 Park Ave. South

New York, NY 10010

  

Item 2.(d) Title of Class of Securities

Common Stock, $0.001 par value per share

 

Item 2.(e) CUSIP No.:

098070303

 

CUSIP No.  098070303
 SCHEDULE 13G/A
Page 4 of 6 Pages

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

  (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 
  (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 
  (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 
  (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 
  (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
  (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 
  (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
 
  (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
  (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
  (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
 
  (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
       

 

CUSIP No.  098070303
 SCHEDULE 13G/A
Page 5 of 6 Pages

 

 

Item 4. Ownership

Information with respect to the Reporting Person’s ownership of the Common Stock as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

Bone Biologics (NASDAQ:BBLG)
過去 株価チャート
から 5 2024 まで 6 2024 Bone Biologicsのチャートをもっと見るにはこちらをクリック
Bone Biologics (NASDAQ:BBLG)
過去 株価チャート
から 6 2023 まで 6 2024 Bone Biologicsのチャートをもっと見るにはこちらをクリック

ニュース - Bone Biologics Corporation

Bone Biologics Announces Closing of $2.0 Million Public Offering
木曜日 7年3月2024日 (3月前) • Business Wire
Form EFFECT - Notice of Effectiveness
火曜日 5年3月2024日 (3月前) • Edgar (US Regulatory)
Form 424B4 - Prospectus [Rule 424(b)(4)]
火曜日 5年3月2024日 (3月前) • Edgar (US Regulatory)
Bone Biologics Announces Pricing of $2.0 Million Public Offering
月曜日 4年3月2024日 (3月前) • Business Wire
Form 8-K - Current report
金曜日 1年3月2024日 (3月前) • Edgar (US Regulatory)
Bone Biologics Reports Progress With NB1 Clinical Program
金曜日 1年3月2024日 (3月前) • Business Wire
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
火曜日 27年2月2024日 (3月前) • Edgar (US Regulatory)
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
土曜日 24年2月2024日 (3月前) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
木曜日 22年2月2024日 (3月前) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
木曜日 15年2月2024日 (4月前) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
木曜日 15年2月2024日 (4月前) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
水曜日 14年2月2024日 (4月前) • Edgar (US Regulatory)

その他のBone Biologics Corporationニュース記事